---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-040661"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2026-04-08T23:59:59+00:00"
generated_at: "2026-05-15T06:57:50.224932+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Regeneron expects ~$102M IPR&D charge in Q1 2026, ~$0.81 EPS hit

## Summary
- Pre-tax acquired IPR&D charge of ~$102M from milestone/up-front payments and equity securities premium.
- Charge expected to reduce GAAP and non-GAAP diluted EPS by ~$0.81 each for Q1 2026.
- Results are preliminary, subject to closing procedures; actuals may differ.
- Regeneron does not forecast such charges due to transaction uncertainty.
- Company reiterates non-GAAP measure excludes certain items not viewed as useful.

## SEC filing metadata
- accession: 0001104659-26-040661
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2026-04-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000110465926040661/0001104659-26-040661-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000110465926040661/tm2611354d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-040661
- JSON: https://secwatch.observer/filing/0001104659-26-040661.json
- Plain text: https://secwatch.observer/filing/0001104659-26-040661.txt

## Key facts
- Earnings Releases
  REGENERON PHARMACEUTICALS, INC. reported preliminary financial results for first quarter 2026.
  - Period: first quarter 2026
  - Result: preliminary results
  source text: Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the first quarter 2026 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $102 million on a pre-tax basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465926040661/0001104659-26-040661-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.